Skip to main content

Table 3 Costs, Utilities and ICER between alternatives in 30-year lifetime approach (discounted)

From: In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model

A. Deterministic Results

30-year followed up

Mastectomy

(1)

Lumpectomy without irradiation

(2)

Lumpectomy with irradiation

(3)

1 vs. 2

2 vs. 3

1 vs. 3

QALY

11.21

11.24

11.80

0.03

0.57

0.60

Total cost (SEK)

(Healthcare perspective)

1,178,710

628,859

857,430

-549,852

228,572

-321,280

Total cost (SEK)

(Societal perspective)

1,374,774

691,882

1,018,486

− 682,891

326,603

356,288

ICER (Healthcare perspective)

 

Dominated by 2*

402,994

Dominated by 3*

ICER (Societal perspective)

 

Dominated by 2*

575,833

Dominated by 3*

B. Probabilistic Results

 

30-year followed up

Mastectomy

(1)

Lumpectomy without irradiation

(2)

Lumpectomy with irradiation

(3)

1 vs. 2

2 vs. 3

1 vs. 3

QALY

10.56

10.67

11.01

0.11

0.35

0.45

95%CI

(5.52–13.75)

(5.61–13.80)

(5.71–14.50)

   

Total cost (SEK)

(Healthcare perspective)

1,342,074

826,459

1,008,674

-515,614

182,215

-333,399

95%CI

(630,402-1,745,438)

(343,150-1,257,338)

(459,686-1,391,397)

   

ICER (Healthcare perspective)

 

Dominated by 2*

527,841

Dominated by 3*

ICER (Societal perspective)

 

Dominated by 2*

777,640

Dominated by 3*

  1. CI indicates confidence interval; ICER, incremental cost-effectiveness ratio (unit: SEK/QALY gained); QALY, quality-adjusted life years; SEK, Swedish krona
  2. *Mastectomy is dominated